

<https://doi.org/10.17816/ecogen17491-102>

## EFFECTS OF THE INTESTINAL MICROBIOTA ON EPIGENETIC MECHANISMS INVOLVED IN THE DEVELOPMENT OF POST-STRESS NEURO-INFLAMMATION

© I.G. Shalaginova, L.V. Matskova, N.M. Gunitseva, I.A. Vakoliuk

Immanuel Kant Baltic Federal University, Kaliningrad, Russia

Cite this article as: Shalaginova IG, Matskova LV, Gunitseva NM, Vakoliuk IA.

Effects of the intestinal microbiota on epigenetic mechanisms involved in the development of post-stress neuro-inflammation.

*Ecological genetics*. 2019;17(4):91-102. <https://doi.org/10.17816/ecogen17491-102>.

Received: 02.04.2019

Revised: 20.09.2019

Accepted: 17.12.2019

✿ A number of alleles of polymorphic genes, dysfunctions of the hypothalamic-pituitary-adrenal axis, neurotransmitter disorders, and manifestations of immune dysregulation are associated with vulnerability to stress. Post-stress states of humans and animals are accompanied by signs of neuroinflammation, the causes and mechanisms of which remain to be elucidated. The article discusses epigenetic mechanisms by which the intestinal microbiota might participate in the initiation and maintenance of post-stress inflammation.

✿ **Keywords:** microbiota; stress; post-stress pathology; neuroinflammation; epigenetic modifications.

## ЭПИГЕНЕТИЧЕСКИЙ МЕХАНИЗМ ВЛИЯНИЯ МИКРОБИОТЫ КИШЕЧНИКА НА РАЗВИТИЕ ПОСТСТРЕССОРНОГО НЕЙРОВОСПАЛЕНИЯ

© И.Г. Шалагинова, Л.В. Мацкова, Н.М. Гуницева, И.А. Ваколюк

ФГАОУ ВО «Балтийский федеральный университет имени Иммануила Канта», Калининград

Для цитирования: Шалагинова И.Г., Мацкова Л.В., Гуницева Н.М., Ваколюк И.А. Эпигенетический механизм влияния микробиоты кишечника на развитие постстрессорного нейровоспаления // Экологическая генетика. — 2019. — Т. 17. — № 4. — С. 91–102. <https://doi.org/10.17816/ecogen17491-102>.

Поступила: 02.04.2019

Одобрена: 20.09.2019

Принята: 17.12.2019

✿ С уязвимостью к стрессу ассоциирован ряд аллелей полиморфных генов, а также дисфункции гипоталамо-гипофизарно-надпочечниковой оси, нейромедиаторные нарушения и проявления иммунной дисрегуляции. Есть убедительные доказательства наличия признаков нейровоспаления при постстрессорных состояниях человека и животных. Причины и механизмы таких нейроиммунных дисфункций не выяснены. В статье рассматривается возможность участия микробиоты кишечника в инициации и поддержании постстрессорного воспаления через эпигенетические механизмы.

✿ **Ключевые слова:** микробиота; стресс; постстрессорные патологии; нейровоспаление; эпигенетические модификации.

There is evidence that the microbiota of the human gastrointestinal tract (GIT) influences both the state of the central nervous system (CNS) and cognitive functions [1–5]. The field of neuroscience focuses on these interactions [6].

It has been demonstrated that intestinal microbiota modulates the synthesis of hormones, immune factors, and neurotransmitters and can affect the development and functioning of the brain, including the severity of symptoms of mental disorders, such as depression, post-stress pathologies, schizophrenia, and autism [6].

According to PubMed (microbiota & stress request), interest in studying the influence of GIT microbiota on the development of stress-related pathologies continues to grow steadily (from five articles in 2004 to 481 in 2018).

In 2004, it was revealed for the first time that germ-free (GF) mice without microbiota demonstrated

significantly higher activity of the hypothalamic–pituitary–adrenal (HPA) axis in response to stress factors compared with mice with microbiota but not with specific pathogens (specific pathogen-free [SPF] mice) [7]. Subsequently, the dependence of the condition of brain microglial cells on the qualitative and quantitative composition of the intestinal microbiota was established [8]. Since microglial cells are involved in the initiation and maintenance of neuroinflammation that accompanies post-stress states, microbiota is considered as one of the possible regulators in the occurrence of post-stress pathologies [9].

Neuroinflammation is an inflammatory response in the CNS that is mediated by cytokines, chemokines, reactive oxygen intermediates, and secondary messengers. The main source of proinflammatory mediators is activated microglia [10]. These immune cells in the CNS provide the primary form of an adaptive immune

response [11]. It is known that chronic neuroinflammation underlies many neurological and mental disorders (Parkinson's disease, depression, schizophrenia, and post-traumatic stress disorder [PTSD]) [9].

However, the involvement of the microbiota of the host organism in microglia activation and in the maintenance of neuroinflammation remains unclear. One possible theory is that bacterial metabolites have the ability to influence the epigenetic modifications of genes associated with immunoregulation [12].

Epigenetic modifications are inherited molecular mechanisms in the regulation of gene expression; they do not affect the nucleotide sequence of DNA but lead to specific conformational changes in chromatin structure [13].

This article analyzes recent studies on the role of intestinal microbiota in the epigenetic control of the development of post-stress neuroinflammation.

### **MICROBIOTA OF HUMAN INTESTINES**

GIT microbiota refers to the totality of all microorganisms that inhabit the human intestines (bacteria, eukaryotes, archaea, and viruses), while microbiome is defined as a complete genetic set of these microorganisms [14]. The total number of bacteria that comprise human microbiota is higher than the number of cells in the human body ( $3.9 \cdot 10^{13}$  and  $3.0 \cdot 10^{13}$ , respectively) [15]. The human genome contains 12 times fewer genes than microbiomes. According to recent estimates, the total number of genes that make up the microbiome is 400,000 [16]. Of the total number of bacteria in an adult's body, 80% are intestinal bacteria [6].

The composition of GIT microbiota changes throughout a person's life [17]. Intestinal colonization by microorganisms occurs during embryo-fetal development via amniotic fluid and/or umbilical cord blood [18–20]. Bacteria have been found in the meconium of healthy newborns [21]. However, the main stage in the formation of human intestinal microbiota occurs during post-embryonic development. During and immediately after birth, the newborn comes into contact with both the mother's microbiota and the environment; consequently, a number of commensal bacteria are acquired, which inhabit the GIT [22]. Studies show that the first years of life are a critical period for the formation of a healthy intestinal ecosystem [23].

According to the "old friends" hypothesis, such a symbiosis between the human body and the plurality of microorganisms that inhabit its intestines is the result of a lengthy joint evolution [24]. There is ample evidence that intestinal microbiota perform a number of essential functions in the host organism. They participate in the

creation and maintenance of the integrity of the interstitial barrier, stimulate the regeneration of intestinal epithelial cells, produce mucus, and nourish the GIT mucosa by secreting some metabolites [25, 26].

Intestinal microbiota is involved in the maturation of the host immune system due to its capacity to stimulate innate immunity during the early stages of ontogenesis. It affects the development of the lymphoid tissue related to the intestines; activates adaptive immunity through stimulation of local and systemic immune responses [27]; participates in the synthesis of certain nutrients, hormones, and vitamins; and plays an important role in the removal of toxins.

Under normal conditions, the microbiota is able to stimulate the immune system, leading to a state of low-intensity physiological inflammation (parainflammation). It is hypothesized that such stimulation of immunity increases the tolerance of the host organism to the damaging effects of pathogenic microbes [28].

However, the intestinal ecosystem is extremely vulnerable to the effects of adverse factors. The existing balance of microorganisms can be disturbed both by psychoemotional factors (i. e., stress, including during the prenatal period) and by diet and drug intake [29]. The composition of the GIT microbiota is also determined by viruses [30] and parasitic infections of the intestine [31].

### **INFLUENTIAL MECHANISMS OF GIT MICROBIOTA ON BRAIN DEVELOPMENT AND FUNCTION**

To date, adequate data has been accumulated on the relationship between the qualitative and quantitative indicators of intestinal microbiota and the severity of symptoms of anxiety and depression in both humans and rodents [32, 33].

An extended study following an outbreak of bacterial gastroenteritis in Canada revealed that severe anxiety and depression are risk factors for persistent intestinal symptoms after eight years from the initial infection [34].

In 2013, the National Institute of Mental Health in the United States of America launched a program to study the mechanisms of interaction between the microbiota and the brain with the purpose of creating new drugs and developing non-invasive treatments for mental disorders.

The interaction between the brain and intestinal microbiota is often described in literature as the microbiota–intestine–brain axis [1, 6, 29, 32, 33]. Such communication takes place through neuroanatomical pathways and the endocrine and immune systems as well as via the release of certain metabolites by bacteria that can affect the nervous system [6, 35, 36].

The autonomic nervous system of the intestine and the vagus nerve provide one route by which the intestinal microbiota affects the brain. It is generally recognized that bacterial metabolites stimulate afferent neurons in the enteric nervous system [37].

It has been known since the 1930s that enteroendocrine cells are located in the intestinal epithelium. They are electrically excitable, but until recently it was believed that these cells were unable to form synapses with cranial nerves. A recent study [37] identified a type of sensory intestinal epithelial cell that contains synapses with sensitive neurons of the vagus nerve (nodose ganglia). The authors referred to these cells as neuropod cells, since, despite being a type of endocrine cells, they have the ability to form neuroepithelial networks. Using glutamatergic synapses with the vagus nerve, the neuropod cells connect the intestinal lumen directly to the brain stem. Due to the existence of such nerve networks, the brain can obtain information from the intestinal lumen within a few milliseconds.

The functional disturbances of the hypothalamus, pituitary, and adrenal glands that constitute the HPA axis contribute to the pathogenesis of post-stress pathologies [38]. The latest data indicate a significant role of intestinal microbiota in the functional disorder of these structures and, consequently, in neuroendocrine dysregulation [7].

In GF mice, stress caused by prolonged immobilization leads to a significantly greater release of corticosterone and adrenocorticotrophic hormones compared with control animals with normal microbiota. Such an excessive response to stress can be partially normalized by preliminary stool transplantation from control mice and is completely restored by colonizing an individual bacterium of the *Bifidobacterium infantis* species in the intestine [39].

One of the possible mechanisms of such an effect of bacteria on the function of the HPA axis is the effect their metabolites have on the functioning of the glutamatergic and serotonergic synapses. GF mice showed a significant decrease in the expression of glutamate receptors (NMDA receptors) and serotonin (5HT<sub>1A</sub> receptors) in the hippocampus and cortex compared with SPF mice. Deficiencies in glutamatergic and serotonergic transmission can lead to disruptions in the function of the HPA axis, which acts on the secretion of corticotrophin-releasing hormone (CRH) in the hypothalamus. Long-term exposure to elevated levels of CRH creates a state of distress, severe depressive symptoms, insomnia, chronic anxiety, exhaustion, and a decrease in libido [6].

It has been revealed that the stress factor affecting the operation of the HPA axis can induce a change in the

microbiota composition. For example, in newborn rats, early weaning from the mother not only leads to long-term changes in the functioning of the HPA axis but also has a lasting effect on the microbiota composition of the offspring [40].

Similar interactions are exhibited during exposure of adult animals to stress. In mice, the microbiota composition in a mouse model of chronic psychoemotional stress and in unstressed mice is significantly different [41]. Stress has been confirmed to decrease the amount of *Bacteroides* in the cecum and increase the amount of *Clostridium* [42].

Immune interactions represent another mechanism through which microbiota can affect the condition and functions of the nervous system. An important role in the communication between bacteria and the host is played by Toll-like receptors (TLRs), which are expressed on epithelial cells, monocytes, macrophages, dendritic cells, neutrophils, and natural killers and are also widely represented in neurons and glial cells [43]. They recognize the conservative structures of microorganisms and represent an important link in the innate immune system. After activation, TLRs bind to adapter proteins and are able to induce cytokine synthesis.

Intestinal microbiota produces neurotransmitters and other regulatory molecules that can affect both the brain and behavior. These substances include gamma-aminobutyric acid, serotonin (5-HT), dopamine, and short-chain fatty acids (SCFA) [25, 26, 44–46].

SCFA are metabolic products of intestinal microbiota; they are used by the host cells as an energy source for ATP synthesis. Simultaneously, some of the salts of such acids (propionate, butyrate) are involved in the epigenetic modifications in mammalian cells. Thus, bacteria of the genera *Clostridium*, *Eubacterium*, and *Butyrivibrio* are able to synthesize and supply butyrate from indigestible fibers into the gastrointestinal tract lumen. Butyrate has an inhibitory effect on histone deacetylase (HDAC) and thus is involved in the epigenetic modification of histones [44].

Several receptors for SCFA in various tissues are known. Free fatty-acid receptor 2 (FFAR2), free fatty-acid receptor 3 (FFAR3), and hydroxycarboxylic-acid receptor 2 (HCR2) (also known as G protein-coupled receptor 109 A) have been extensively studied. In dendritic cells, these G-protein-associated transmembrane proteins affect cell metabolism, inflammation, and oxidative stress [25]. In lymphocytes, the activation of these receptors by agonists such as SCFA regulates the expansion, differentiation, and functionality of T cells [26], which is one of the mechanisms of SCFA action on the immune system.

There is evidence of the presence of SCFA receptors (e. g., FFAR3) in the CNS of rats and in the peripheral nervous system of mice [47]. To date, there is no evidence of the presence of FFAR2 and FFAR3 receptors on microglial cells [48]; however, it has been revealed that SCFA affects the maturation and activity of microglial cells in laboratory animals [8, 49]. Changes in both the structure and density of microglial cells in sterile mice were recorded. The same phenotype can be reproduced by inhibiting the expression of FFAR2 and FFAR3 – SCFA receptors [6].

In rats, the HCAR2 receptor (more specifically, its mRNA and the corresponding protein) was found in the microglial cells of the substantia nigra. Previous work shows that  $\beta$ -hydroxybutyric acid reduces the manifestation of motor dysfunction in rats in a model of Parkinson's disease. This positive effect is associated with the suppression of microglial activation and a decrease in the production of proinflammatory cytokines, which prevents the loss of dopaminergic neurons in the substantia nigra. The authors demonstrated that  $\beta$ -hydroxybutyric acid acts on microglial cells via HCAR2 receptors and reduces the activation of the NF- $\kappa$ B signaling pathway (a key inflammatory mediator). HCAR2 knockdown cancels the anti-inflammatory effect and decreases NF- $\kappa$ B activity [50].

Other key metabolites of the intestinal microbiota, including S-adenosylmethionine, acetyl-CoA, nicotinamide adenine dinucleotide, and ATP, are necessary cofactors for enzymes that regulate DNA methylation and histone modifications [51]. Thus, folate (a metabolite of *Bifidobacterium* spp. and other bacteria) is a methyl-group donor and is crucial for the production of S-adenosylmethionine, which is also a methyl-group donor and a substrate for DNA methyltransferases [52].

## POST-STRESS PATHOLOGIES AND IMMUNE RESPONSE

In recent years, neuroimmune regulation disorders have been actively investigated in various mental disorders, including in post-stress conditions. There is convincing evidence of the signs of neuroinflammation in neurotic and stress-related disorders in humans and in animal models (mice and rats) of similar psychopathologies. Most studies evaluate the levels of proinflammatory cytokines in the blood of patients with PTSD, and postmortem studies on sections of the human brain are rare.

It was revealed that the levels of proinflammatory cytokines, such as interleukin-1 $\beta$  (IL-1 $\beta$ ), interleukin-6 (IL-6), and tumor necrosis factor (TNF), are significantly increased in the blood of patients with PTSD com-

pared with both the control and patients with a history of injury without the development of symptoms of the disease [9].

These data indicate the presence of peripheral inflammation in PTSD, but they do not indicate its role in the pathogenesis of the disease. The connection between peripheral inflammation and PTSD pathogenesis is indicated by the fact that the higher levels of cytokines detected in the blood plasma of military personnel before their participation in hostilities are associated with an increased risk of PTSD development after their return from flashpoint areas [53]. In addition, a higher level of glucocorticoid-dependent production of cytokines and T-cell proliferation before the hostilities is associated with the increased severity of PTSD symptoms in soldiers after returning from combat areas [54].

However, the lack of convincing data on the signs of neuroinflammation in the brains of patients with stress-related neurotic disorders does not conclusively explain how the level of peripheral cytokines reflects the involvement of neuroimmune processes in the development of post-stress conditions.

Therefore, the use of animal models seems to offer promising clarification of this issue. In the mouse model, on day 8 after exposure to stress, an increase in the level of monocytes circulating in the blood and increased anxiety in behavioral tests were revealed. On day 24 after the exposure to stress, anxiety behavior and increased proinflammatory cytokine mRNA levels in microglial cells (IL-1 $\beta$ , TNF, and IL-6) were still noted, although there were no peripheral signs of inflammation [55]. There is also evidence of increased expression of the same cytokines in the rat hippocampus in the PTSD model; this effect persisted for two weeks after exposure to stress [9].

The brain microglial cells are derived from macrophages, which are cells that are capable of actively capturing and digesting particles that are foreign or toxic to the body, such as bacteria and the remains of dead cells. Microglial cells are the first line of defense in brain injuries and infectious diseases and become activated in the case of some neurological and mental disorders [6]. Microglial cells migrate to the CNS during prenatal development. They are actively involved in brain development via participation in the formation of synapses and nerve cells and in the prevention of excessive activation of neurons [6].

## MICROBIOTA AND POST-STRESS INFLAMMATION

Recently, the interaction between the GIT microbiota and the brain has been considered as one of the fac-

tors in the emergence of a number of psychiatric and neurological diseases, which suggests the concept of a human as a superorganism or a holobiont with all its complexity.

In the perinatal period, the functional development of the mammalian brain is subject to both internal and external signals. Epidemiological studies have revealed a relationship between microbial pathogenic infections during this time and common disorders of the nervous system development, such as autism and schizophrenia [2, 5, 35]. The rodent models revealed that the effect of microbial pathogens in the early postnatal periods of development causes a disorder of cognitive functions and contributes to the development of symptoms of anxiety [56, 57].

A comparison between the GIT microbiota in patients with PTSD and healthy subjects exposed to a single stress factor [58] revealed a decrease in the relative number of bacteria (*Actinobacteria*, *Lentisphaerae*, and *Verrucomicrobia*) in patients with PTSD. The data from this study are consistent with the findings of post-stress pathologies in animal models [59]. It was concluded that a deficiency of the above microorganisms may lead to an increased vulnerability to PTSD.

Most studies of the microbiota–intestine–brain axis were focused on animal models. The use of GF mice enabled an evaluation of the effect of microbiota on behavior, as well as the determination of the effect of specific bacteria or dietary changes on the interaction between the microbiota, the intestines, and the brain. It has been established that the most pronounced aspects of such mice are disorders in the functioning of the immune system. Similar disorders are observed in patients with behavioral symptoms of anxiety [60].

GF mice show signs of neuroinflammation in those brain structures that are involved in the pathogenesis of stress-related disorders [61]. An increased level of pro-inflammatory IL-1 $\beta$  in the amygdala of GF mice is detected along with a decrease in the BDNF neurotrophic factor [62].

The SCFA produced by intestinal microbiota affect neuroimmune regulation through modulation of the state and functioning of the brain microglial cells. These metabolites can inhibit HDAC, i. e., they can regulate epigenetic changes at the system level, which is combined with a change in the microglial-cell phenotype from activated to anti-inflammatory [45, 46].

Folates, butyrates, and acetates produced by bacteria are involved in DNA-methylation processes in the cells of the host organism. For example, folates (a vital product of *Bifidobacterium* spp.) are necessary for the synthesis of S-adenosylmethionine, which is a methyl-group A donor for DNA methyltransferases [58].

These data support the hypothesis of the effect of intestinal microbiota on physiological processes in the host organism by influencing the epigenetic modifications of the host genome.

### EPIGENETIC MODIFICATIONS AND POST-STRESS INFLAMMATION

In the modern sense, epigenetic modifications are molecular mechanisms of gene-expression regulation that do not affect the nucleotide sequence of the DNA; however, specific conformational changes in chromatin structure occur [13, 63].

Epigenetic modifications can be inherited and reversible. They are involved in the processes of cell differentiation in multicellular organisms and changes in gene-expression profiles in response to changing environmental conditions [51, 52, 61].

The regulation of gene expression by methylation of regulatory DNA sequences, histone modification, non-coding RNA, and post-transcriptional RNA processing is included in the most well-known epigenetic mechanisms.

DNA methylation consists of the attachment of a methyl group to carbon in the cytosine molecule at position 5 to form 5-methylcytosine. The methylation of the promotor regions of genes often leads to an inhibition of transcription. However, the hydroxymethylation of the same sequence can stimulate gene expression [64]. These changes are catalyzed by a group of enzymes, namely, DNA methyltransferases, for example, DNMT1, DNMT3A, and DNMT3B (which catalyze methylation), and TET1-3 and IDH1-3 (which catalyze hydroxymethylation).

Histone modifications are more diverse and complex than DNA methylation. Various amino acids of histone tails can be methylated, acetylated, and phosphorylated. These modifications can increase or decrease gene expression depending on the type of change and its position [63]. For example, the acetylation of histone residues leads to the increased availability of nucleosomal DNA for transcription factors, thereby increasing the expression levels of the corresponding genes. Histone acetylation consists of the transfer of the acetyl group from acetyl coenzyme A to histone lysine and is catalyzed by lysine acetyltransferase. The acetylation process is balanced by the deacetylation of histones and the removal of the acetyl group from lysine, which is catalyzed by HDAC [65].

Complex combinations of DNA methylation and histone modifications interact with more than 1000 microRNAs. In turn, each microRNA can bind to the transcripts of hundreds of genes depending on the type

of tissue, thereby increasing the complexity of the transcriptional response of the body without increasing the number of genes.

The epigenetic regulation of gene expression is considered to be a mechanism of interaction between the environment and the genome. It is likely that a traumatic event (stress factor) causes the persistent epigenetic modifications in loci associated with immune dysregulation and increases the risk of PTSD. The question of the degree of reversibility and durability of such modifications remains relevant.

To date, there is evidence of a lower level of methylation of the promotor regions of genes associated with immune response, including proinflammatory *IL-18* and *IL-8*, in the blood of patients with PTSD compared with the control [66–68]. The main limitation of these studies consists of the measurement of the level of DNA methylation (mDNA) in serum or whole blood without considering the cellular composition. Therefore, the results discussed may not reflect PTSD-specific changes in the peripheral immune system cells. In this regard, future studies should determine the level of mDNA in homogeneous cell populations [69]. There are no post-mortem studies available in which the brains of patients with PTSD are compared with the norm; therefore, no data are available on the level of methylation of cytokine genes in the brain microglial cells of patients [66].

A comparison of the methylation level of genes associated with the development of inflammation in blood and microglial cells in PTSD animal models will enable an understanding of how the previously identified differences in peripheral mDNA levels correlate with the epigenetic modifications of DNA in the brain.

Intestinal microbiota is considered as a factor that actively affects the development of the nervous system, the functional state of the brain, and behavior via epigenetic modifications of genes associated with neuroinflammation [61]. As detailed above, metabolites of the GIT microbiota (butyrate and propionate) inhibit HDAC and thus affect the activation of the host genome transcription [51].

In patients with chronic gastritis, the presence of *Helicobacter pylori* in the GIT is specifically associated with DNA hypermethylation in the region of the O6-methylguanine-DNA methyltransferase (MGMT) gene promotor, which reduces the expression of the MGMT protein in gastric epithelial cells [70]. MGMT is a nuclear protein that plays a key role in repairing DNA damage caused by simple alkylating agents and is considered as a tumor-growth-suppressor gene.

Animal studies have revealed that such epigenetic changes in the cells of the gastric mucosa are associated

with inflammation induction as a result of an *H. pylori* infection – but not with the bacterium itself. Significant suppression of inflammation by the immunosuppressive drug, cyclosporin A, did not affect the colonization of *H. pylori*; however, it blocked DNA hypermethylation [70].

Another example is the protein (Rv3423.1) of *Mycobacterium tuberculosis*, which exhibits histone acetyltransferase activity in host cells and acetylates histone H3 at the K9/K14 positions [71]. In addition, Rv1988, another secreted mycobacterial protein that interacts with chromatin, has methyltransferase activity and methylates histone H3 at the H3R42 position, which suppresses the expression of affected genes [72].

Epigenetic mechanisms are key mediators in the development of chronic inflammation due to the induction of the gene expression of proinflammatory cytokines, including IL-1, IL-2, IL-6, TNF, and COX2 induction, and the NF- $\kappa$ B transcription factor [58]. For example, the increased expression of TNF during the development of irritable bowel symptoms in *Danio rerio* fish is associated with a loss of function of *uhrf1*, a gene that encodes the ubiquitin-like protein (an epigenetic regulator), and leads to the hypomethylation of the TNF-gene promotor. Consequently, an increase in TNF expression mediated by microbiota leads to the recruitment of immune cells, chronic inflammation, apoptosis, and the dysfunction of intestinal epithelial cells as a barrier [73].

The demethylation of a small promotor region of the *IL-2* gene was detected in mouse T cells after their activation. The composition of the microbiota changed; as a result, the *IL-2* gene expression, which is one of the inflammatory mediators, increased. In addition, the maturation of naive CD4 T cells to T-helper cells is characterized by the rapid acetylation of histone H3 in *IL-4/IL-13* gene clusters [74].

Based on these studies, demethylating agents and histone deacetylase inhibitors are currently considered in the literature as epigenetic therapy drugs that target chromatin in rapidly dividing cells [75]. Such agents that affect the epigenetic modifications of genes associated with inflammation can be the metabolites of intestinal microorganisms. Generally, microbiota is a new target for the development of methods for the elimination of neuroinflammation and post-stress pathologies via exposure to the epigenome.

## MICROBIAL THERAPY IN MENTAL DISEASES

The discovery of the relationship between the microbiota, immunity, inflammation, epigenetic modifications, and mental health suggested that exposure to GIT mi-

crobiota may be a tool in combating mental diseases. There are probiotics (living beneficial microorganisms), prebiotics (factors contributing to bacterial growth), and synbiotics (a combination of probiotics and prebiotics) that favorably alter the intestinal microbiota [76]. In this context, they are all called psychobiotics.

The development of psychobiotics is at an early stage. Hence, there is still insufficient evidence to draw an unambiguous conclusion about the causal relationship between the use of any pro- or pre-biotics and changes in the GIT microbiota [77].

The main action mechanisms of probiotics have been clarified. This is a substitution of pathogenic microorganisms during the following processes: the struggle for food sources, the interactions with metabolites, the production of bacteriocins, the inhibition of bacterial translocation, the strengthening of the GIT mucosa [78, 79], the effect on calcium-dependent potassium channels in sensory neurons of the intestine [80], the induction of cannabinoid and opioid receptors in intestinal epithelial cells [81], and the modulation of the immune system [82].

Probiotics include bacteria almost exclusively of the genera *Lactobacillus* and *Bifidobacterium*, and they have a long history of safe use [83]. Clinical trials have shown that probiotics help prevent or reduce the severity of symptoms of various disorders, including chronic intestinal inflammation and irritable bowel syndrome. In addition, it was demonstrated that the transplantation of samples of GIT microbiota from healthy people can help patients with ulcerative colitis [84]. Probiotics inhibit the reproduction of *Enterococcus*, *Bacillus*, *Listeria*, *Staphylococcus*, and *Salmonella* in the GIT, increase the mucus barrier integrity, and modulate the functions of immunocompetent cells [85].

The therapeutic potential of probiotics in autoimmune diseases of the nervous system, such as multiple sclerosis (MS), is being actively studied [86]. Experimental allergic encephalomyelitis (EAE) is considered as a model of MS. There is evidence of changes over time of the qualitative and quantitative composition of the intestinal microbiota in rats with induced EAE associated with the presence or absence of neurological symptoms [87]. Administration of the probiotic *Enterococcus faecium* L3 increased the proportion of animals with asymptomatic and mild forms of the disease compared with the control group. In these rats, a decrease in the blood levels of NK cells and B cells and an increase in the number of T cells were detected. Complaints of gastrointestinal problems were reduced in patients with MS taking the same probiotic; this was accompanied by a change in the composition of

the microbial community in the intestine due to the removal of the pathogenic species *Clostridium perfringens*, *Staphylococcus aureus*, *Klebsiella oxytoca*, and *Candida* [88].

Separate experimental data suggest the possibility of using microbiota correction for the treatment of mental disorders. Animal studies have confirmed that after treatment with probiotics, newborn rats who were stressed at a young age exhibit normal behavior in tests evaluating their anxiety levels [89]. The administration of *Lactobacillus rhamnosus* for 10 days reduces the symptoms of increased anxiety in rats [90].

In humans, a randomized, placebo-controlled study revealed that probiotics can reduce von Willebrand factor and increase BDNF and MCP-1 (the chemotactic protein-1 of monocytes) in patients with schizophrenia [91]. Another study reported reduced tendencies in the severity of symptoms of schizophrenia in male patients after 14 weeks of taking probiotics [92].

A meta-analysis of randomized controlled studies of patients diagnosed with major depression showed that probiotics reduce depressive symptoms [93]. A meta-analysis of seven studies involving healthy volunteers revealed that supplements with probiotics improve the overall psychological condition compared with the placebo [94].

## CONCLUSION

There is convincing evidence of the signs of neuroinflammation in patients with post-stress pathologies and in experimental animal models of acute and chronic stress.

Clarification of the causes of such disorders in immunoregulation at the molecular level is urgently required. It has become clear that the composition of intestinal microbiota affects the functioning of brain microglial cells and the behavior of experimental animals in general. The study of the microbiota–intestine–brain interaction is a promising area of research in the field of biological psychiatry.

Due to the active development of high-performance genome-sequencing technologies, the composition of the human GIT microbiota has been studied in sufficient detail. A concept has been formed about the taxonomic distribution and diversity of microbial communities of the intestine under normal conditions and in the case of various pathologies. Some metabolites of the intestinal microbiota can affect the epigenetic modifications of the host cell genome. A study of the role of microbiota in such gene modifications associated with neuroinflammation will deepen the understanding of the mechanisms of

post-stress pathologies and will facilitate the identification of new targets for their therapy.

#### FUNDING

This work is funded by the Competitiveness Enhancement Program of the Immanuel Kant Baltic Federal University, one of the world's leading scientific and educational centers (5-100).

#### REFERENCES

- Jenkins T, Nguyen J, Polglaze K, Bertrand P. Influence of tryptophan and serotonin on mood and cognition with a possible role of the gut-brain axis. *Nutrients*. 2016;8(1). pii: E56. <https://doi.org/10.3390/nu8010056>.
- Schmidt C. Thinking from the gut. *Nature*. 2015; 518(7540): S12-S15. <https://doi.org/10.1038/518s13a>.
- Smith P. The tantalizing links between gut microbes and the brain. *Nature*. 2015;526(7573):312-314. <https://doi.org/10.1038/526312a>.
- Mayer E, Knight R, Mazmanian S, et al. Gut microbes and the brain: paradigm shift in neuroscience. *J Neurosci*. 2014;34(46):15490-15496. <https://doi.org/10.1523/jneurosci.3299-14.2014>.
- Diaz Heijtz R, Wang S, Anuar F, et al. Normal gut microbiota modulates brain development and behavior. *Proc Natl Acad Sci USA*. 2011;108(7):3047-3052. <https://doi.org/10.1073/pnas.1010529108>.
- Wang H, Wang Y. Gut microbiota-brain axis. *Chin Med J*. 2016;129(19):2373-2380. <https://doi.org/10.4103/0366-6999.190667>
- Sudo N, Chida Y, Aiba Y, et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. *J Physiol*. 2004;558(Pt 1):263-275. <https://doi.org/10.1113/jphysiol.2004.063388>.
- Erny D, Hrabě de Angelis A, Jaitin D, et al. Host microbiota constantly control maturation and function of microglia in the CNS. *Nat Neurosci*. 2015;18(7):965-977. <https://doi.org/10.1038/nn.4030>.
- Deslauriers J, Powell S, Risbrough V. Immune signaling mechanisms of PTSD risk and symptom development: insights from animal models. *Curr Opin Behav Sci*. 2017;14:123-132. <https://doi.org/10.1016/j.cobeha.2017.01.005>.
- DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. *J Neurochem*. 2016;139 Suppl 2:136-153. <https://doi.org/10.1111/jnc.13607>.
- Calcia MA, Bonsall DR, Bloomfield PS, et al. Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness. *Psychopharmacology*. 2016;233(9):1637-1650. <https://doi.org/10.1007/s00213-016-4218-9>.
- Rooks MG, Veiga P, Wardwell-Scott LH, et al. Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission. *ISME J*. 2014;8(7):1403-17. <https://doi.org/10.1038/ismej.2014.3>.
- Deans C, Maggert KA. What do you mean, "epigenetic"? *Genetics*. 2015;199(4):887-896. <https://doi.org/10.1534/genetics.114.173492>.
- Dave M, Higgins P, Middha S, Rioux K. The human gut microbiome: current knowledge, challenges, and future directions. *Transl Res*. 2012;160(4):246-257. <https://doi.org/10.1016/j.trsl.2012.05.003>.
- Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. *PLoS Biol*. 2016;14(8): e1002533. <https://doi.org/10.1371/journal.pbio.1002533>.
- Eckburg P. Diversity of the human intestinal microbial flora. *Science*. 2005;308(5728):1635-1638. <https://doi.org/10.1126/science.11110591>.
- Douglas-Escobar M, Elliott E, Neu J. Effect of intestinal microbial ecology on the developing brain. *JAMA Pediatr*. 2013;167(4):374-379. <https://doi.org/10.1001/jamapediatrics.2013.497>.
- Al-Asmakh M, Anuar F, Zadjali F, et al. Gut microbial communities modulating brain development and function. *Gut Microbes*. 2012;3(4):366-373. <https://doi.org/10.4161/gmic.21287>.
- Jiménez E, Fernández L, Marín M, et al. Isolation of commensal bacteria from umbilical cord blood of healthy neonates born by cesarean section. *Curr Microbiol*. 2005;51(4):270-274. <https://doi.org/10.1007/s00284-005-0020-3>.
- Satokari R, Grönroos T, Laitinen K, et al. Bifidobacterium and lactobacillus DNA in the human placenta. *Lett Appl Microbiol*. 2009;48(1):8-12. <https://doi.org/10.1111/j.1472-765x.2008.02475.x>.
- Jiménez E, Marín M, Martín R, et al. Is meconium from healthy newborns actually sterile? *Res Microbiol*. 2008;159(3):187-193. <https://doi.org/10.1016/j.resmic.2007.12.007>.
- Hooper L, Littman D, Macpherson A. Interactions between the microbiota and the immune system. *Science*. 2012;336(6086):1268-1273. <https://doi.org/10.1126/science.1223490>.
- Clarke G, O'Mahony S, Dinan T, Cryan J. Priming for health: gut microbiota acquired in early life regulates physiology, brain and behaviour. *Acta Paediatr*. 2014;103(8): 812-819. <https://doi.org/10.1111/apa.12674>.
- Rook G, Lowry C, Raison C. Microbial "Old Friends", immunoregulation and stress resilience. *Evol Med Public Health*. 2013;2013(1):46-64. <https://doi.org/10.1093/emph/eot004>.
- Puddu A, Sanguineti R, Montecucco F, Viviani G. Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. *Mediators Inflamm*. 2014;2014:162021. <https://doi.org/10.1155/2014/162021>.



26. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. *Cell*. 2016;165(6):1332-1345. <https://doi.org/10.1016/j.cell.2016.05.041>.
27. Macpherson A, Harris N. Interactions between commensal intestinal bacteria and the immune system. *Nature Rev Immunol*. 2004;4(6):478-485. <https://doi.org/10.1038/nri1373>.
28. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. *Cell*. 2004;118(2):229-241. <https://doi.org/10.1016/j.cell.2004.07.002>.
29. Petra A, Panagiotidou S, Hatziaelaki E, et al. Gut-microbiota-brain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. *Clin Ther*. 2015;37(5):984-995. <https://doi.org/10.1016/j.clinthera.2015.04.002>.
30. Ogilvie L, Jones B. The human gut virome: a multifaceted majority. *Front Microbiol*. 2015;6. <https://doi.org/10.3389/fmicb.2015.00918>.
31. Molloy M, Grainger J, Bouladoux N, et al. Intraluminal containment of commensal outgrowth in the gut during infection-induced dysbiosis. *Cell Host Microbe*. 2013;14(3):318-328. <https://doi.org/10.1016/j.chom.2013.08.003>.
32. Foster J, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. *Trends Neurosci*. 2013;36(5):305-312. <https://doi.org/10.1016/j.tins.2013.01.005>.
33. Rackers H, Thomas S, Williamson K, et al. Emerging literature in the microbiota-brain axis and perinatal mood and anxiety disorders. *Psychoneuroendocrinology*. 2018;95:86-96. <https://doi.org/10.1016/j.psyneuen.2018.05.020>.
34. Marshall J, Thabane M, Garg A, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. *Gut*. 2010;59(5):605-611. <https://doi.org/10.1136/gut.2009.202234>.
35. De Angelis M, Piccolo M, Vannini L, et al. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. *PLoS One*. 2013;8(10): e76993. <https://doi.org/10.1371/journal.pone.0076993>.
36. Abot A, Cani P, Knauf C. Impact of intestinal peptides on the enteric nervous system: novel approaches to control glucose metabolism and food intake. *Front Endocrinol (Lausanne)*. 2018;9. <https://doi.org/10.3389/fendo.2018.00328>.
37. Kaelberer MM, Buchanan KL, Klein ME, et al. A gut-brain neural circuit for nutrient sensory transduction. *Science*. 2018;361(6408). pii: eaat5236. <https://doi.org/10.1126/science.aat5236>.
38. Schumacher S, Niemeyer H, Engel S, et al. HPA axis regulation in posttraumatic stress disorder: A meta-analysis focusing on potential moderators. *Neurosci Biobehav Rev*. 2019;100:35-57. <https://doi.org/10.1016/j.neubiorev.2019.02.005>.
39. Desbonnet L, Garrett L, Clarke G, et al. Effects of the probiotic *Bifidobacterium infantis* in the maternal separation model of depression. *Neurosci*. 2010;170(4):1179-1188. <https://doi.org/10.1016/j.neuroscience.2010.08.005>.
40. O'Mahony S, Hyland N, Dinan T, Cryan J. Maternal separation as a model of brain-gut axis dysfunction. *Psychopharmacology (Berl)*. 2010;214(1):71-88. <https://doi.org/10.1007/s00213-010-2010-9>.
41. Bangsgaard Bendtsen K, Krych L, Sørensen D, et al. Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse. *PLoS One*. 2012;7(10):e46231. <https://doi.org/10.1371/journal.pone.0046231>.
42. Deng H, Yang S, Zhang Y, et al. *Bacteroides fragilis* prevents *Clostridium difficile* infection in a mouse model by restoring gut barrier and microbiome regulation. *Front Microbiol*. 2018;9. <https://doi.org/10.3389/fmicb.2018.02976>.
43. McKernan D, Dennison U, Gaszner G, et al. Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. *Transl Psychiatry*. 2011;1(8): e36-e36. <https://doi.org/10.1038/tp.2011.37>.
44. Bourassa M, Alim I, Bultman S, Ratan R. Butyrate, neuroepigenetics and the gut microbiome: can a high fiber diet improve brain health? *Neurosci Lett*. 2016;625:56-63. <https://doi.org/10.1016/j.neulet.2016.02.009>.
45. Usami M, Kishimoto K, Ohata A, et al. Butyrate and trichostatin A attenuate nuclear factor  $\kappa$ B activation and tumor necrosis factor  $\alpha$  secretion and increase prostaglandin  $E_2$  secretion in human peripheral blood mononuclear cells. *Nutr Res*. 2008;28(5):321-328. <https://doi.org/10.1016/j.nutres.2008.02.012>.
46. Vinolo M, Rodrigues H, Nachbar R, Curi R. Regulation of inflammation by short chain fatty acids. *Nutrients*. 2011;3(10):858-876. <https://doi.org/10.3390/nu3100858>.
47. Dalile B, van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. *Nat Rev Gastroenterol Hepatol*. 2019;16(8):461-478. <https://doi.org/10.1038/s41575-019-0157-3>.
48. Erny D, Hrabě de Angelis AL, Prinz M. Communicating systems in the body: how microbiota and microglia cooperate. *Immunol*. 2017;150(1):7-15. <https://doi.org/10.1111/imm.12645>.
49. Cryan J, Dinan T. Microbiota and neuroimmune signaling – Metchnikoff to microglia. *Nat Rev Gastro-*

- enterol Hepatol.* 2015;12(9):494-496. <https://doi.org/10.1038/nrgastro.2015.127>.
50. Fu SP, Wang JF, Xue WJ, et al. Anti-inflammatory effects of BHBA in both *in vivo* and *in vitro* Parkinson's disease models are mediated by GPR109A-dependent mechanisms. *J Neuroinflammation.* 2015;12(1):9. <https://doi.org/10.1186/s12974-014-0230-3>.
51. Paul B, Barnes S, Demark-Wahnefried W, et al. Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases. *Clin Epigenetics.* 2015;7(1):112. <https://doi.org/10.1186/s13148-015-0144-7>.
52. Hesson LB. Gut microbiota and obesity-related gastrointestinal cancer: a focus on epigenetics. *Translational Gastrointestinal Cancer.* 2013;2(4):204-210. <https://doi.org/10.3978/j.issn.2224-4778.2013.10.03>.
53. Eraly S, Nievergelt C, Maihofer A, et al. Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk. *JAMA Psychiatry.* 2014;71(4):423-431. <https://doi.org/10.1001/jama-psychiatry.2013.4374>.
54. Van Zuiden M, Heijnen C, Maas M, et al. Glucocorticoid sensitivity of leukocytes predicts PTSD, depressive and fatigue symptoms after military deployment: a prospective study. *Psychoneuroendocrinology.* 2012;37(11):1822-1836. <https://doi.org/10.1016/j.psyneuen.2012.03.018>.
55. Wohleb E, Patterson J, Sharma V, et al. Knockdown of interleukin-1 receptor type-1 on endothelial cells attenuated stress-induced neuroinflammation and prevented anxiety-like behavior. *J Neurosci.* 2014;34(7):2583-2591. <https://doi.org/10.1523/jneurosci.3723-13.2014>.
56. Bilbo S, Levkoff L, Mahoney J, et al. Neonatal infection induces memory impairments following an immune challenge in adulthood. *Behav Neurosci.* 2005;119(1):293-301. <https://doi.org/10.1037/0735-7044.119.1.293>.
57. Goehler L, Park S, Opitz N, et al. *Campylobacter jejuni* infection increases anxiety-like behavior in the holeboard: possible anatomical substrates for viscerosensory modulation of exploratory behavior. *Brain Behav Immunol.* 2008;22(3):354-366. <https://doi.org/10.1016/j.bbi.2007.08.009>.
58. Malan-Muller S, Valles-Colomer M, Raes J, et al. The gut microbiome and mental health: implications for anxiety- and trauma-related disorders. *OMICS.* 2018;22(2):90-107. <https://doi.org/10.1089/omi.2017.0077>.
59. Reber S, Slattery D. Editorial: using stress-based animal models to understand the mechanisms underlying psychiatric and somatic disorders. *Front Psychiatry.* 2016;7:192. <https://doi.org/10.3389/fpsy.2016.00192>.
60. Minakova E, Warner B. Maternal immune activation, central nervous system development and behavioral phenotypes. *Birth Defects Res.* 2018;110(20):1539-1550. <https://doi.org/10.1002/bdr2.1416>.
61. Alam R, Abdolmaleky H, Zhou J. Microbiome, inflammation, epigenetic alterations, and mental diseases. *Am J Med Genet B Neuropsychiatr Genet.* 2017;174(6):651-660. <https://doi.org/10.1002/ajmg.b.32567>.
62. Gur T, Shay L, Palkar A, et al. Prenatal stress affects placental cytokines and neurotrophins, commensal microbes, and anxiety-like behavior in adult female offspring. *Brain Behav Immunol.* 2017;64:50-58. <https://doi.org/10.1016/j.bbi.2016.12.021>.
63. Дюжикова Н.А., Даев Е.В. Геном и стресс-реакция у животных и человека // Экологическая генетика. — 2018. — Т. 16. — № 1. — С. 4-26. [Dyuzhikova NA, Daev EV. Genome and stress-reaction in animals and humans. *Ecological genetics.* 2018;16(1):4-26. (In Russ.)] <https://doi.org/10.17816/ecogen1614-26>.
64. Cheng Y, Bernstein A, Chen D, Jin P. 5-Hydroxymethylcytosine: a new player in brain disorders? *Exp Neurol.* 2015;268:3-9. <https://doi.org/10.1016/j.expneurol.2014.05.008>.
65. Roth S, Denu J, Allis C. Histone acetyltransferases. *Annu Rev Biochem.* 2001;70:81-120. <https://doi.org/10.1146/annurev.biochem.70.1.81>.
66. Rusiecki J, Byrne C, Galdzicki Z, et al. PTSD and DNA methylation in select immune function gene promoter regions: a repeated measures case-control study of u. s. military service members. *Front Psychiatry.* 2013;4:56. <https://doi.org/10.3389/fpsy.2013.00056>.
67. Uddin M, Aiello A, Wildman D, et al. Epigenetic and immune function profiles associated with post-traumatic stress disorder. *Proc Natl Acad Sci USA.* 2010;107(20):9470-9475. <https://doi.org/10.1073/pnas.0910794107>.
68. Zannas A, Provençal N, Binder E. Epigenetics of post-traumatic stress disorder: current evidence, challenges, and future directions. *Biol Psychiatry.* 2015;78(5):327-335. <https://doi.org/10.1016/j.biopsych.2015.04.003>.
69. Niwa T, Tsukamoto T, Toyoda T, et al. Inflammatory processes triggered by *Helicobacter pylori* infection cause aberrant DNA methylation in gastric epithelial cells. *Cancer Res.* 2010;70(4):1430-1440. <https://doi.org/10.1158/0008-5472.can-09-2755>.
70. Sepulveda A, Yao Y, Yan W, et al. CpG methylation and reduced expression of O<sup>6</sup>-methylguanine DNA methyltransferase is associated with *Helicobacter pylori* infection. *Gastroenterology.* 2010;138(5):1836-1844. <https://doi.org/10.1053/j.gastro.2009.12.042>.
71. Jose L, Ramachandran R, Bhagavat R, et al. Hypothetical protein Rv3423.1 of *Mycobacterium tuberculosis* is a histone acetyltransferase. *FEBS J.* 2015;283(2):265-281. <https://doi.org/10.1111/febs.13566>.

72. Yaseen I, Kaur P, Nandicoori V, Khosla S. Mycobacteria modulate host epigenetic machinery by Rv1988 methylation of a non-tail arginine of histone H3. *Nat Commun.* 2015;6:8922. <https://doi.org/10.1038/ncomms9922>.
73. Marjoram L, Alvers A, Deerhake M, et al. Epigenetic control of intestinal barrier function and inflammation in zebrafish. *Proc Natl Acad Sci USA.* 2015;112(9):2770-5. <https://doi.org/10.1073/pnas.1424089112>.
74. Zhu J, Yamane H, Paul W. Differentiation of effector CD4 T cell populations. *Annu Rev Immunol.* 2010;28:445-489. <https://doi.org/10.1146/annurev-immunol-030409-101212>.
75. Karberg S. Switching on epigenetic therapy. *Cell.* 2009;139(6):1029-1031. <https://doi.org/10.1016/j.cell.2009.11.038>.
76. Parkes G. An overview of probiotics and prebiotics. *Nurs Stand.* 2007;21(20):43-47. <https://doi.org/10.7748/ns2007.01.21.20.43.c4510>.
77. Sarkar A, Lehto S, Harty S, et al. Psychobiotics and the manipulation of bacteria-gut-brain signals. *Trends Neurosci.* 2016;39(11):763-781. <https://doi.org/10.1016/j.tins.2016.09.002>.
78. Collado M, Isolauri E, Salminen S. Specific probiotic strains and their combinations counteract adhesion of *Enterobacter sakazakii* to intestinal mucus. *FEMS Microbiol Lett.* 2008;285(1):58-64. <https://doi.org/10.1111/j.1574-6968.2008.01211.x>.
79. Liu Z, Shi C, Yang J, et al. Molecular regulation of the intestinal epithelial barrier: implication in human diseases. *Front Biosci (Landmark Ed).* 2011;16:2903-2909. <https://doi.org/10.2741/3888>.
80. Kunze W, Mao Y, Wang B, et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. *J Cell Mol Med.* 2009;13(8B):2261-2270. <https://doi.org/10.1111/j.1582-4934.2009.00686.x>.
81. Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. *Nat Med.* 2007;13(1):35-37. <https://doi.org/10.1038/nm1521>.
82. Sanders M. Impact of probiotics on colonizing microbiota of the gut. *J Clin Gastroenterol.* 2011;45 Suppl: S115-9. <https://doi.org/10.1097/mcg.0b013e318227414a>.
83. Linares D, Ross P, Stanton C. Beneficial microbes: the pharmacy in the gut. *Bioengineered.* 2016;7(1):11-20. <https://doi.org/10.1080/21655979.2015.1126015>.
84. Suskind D, Singh N, Nielson H, Wahbeh G. Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. *J Pediatr Gastroenterol Nutr.* 2015;60(1):27-29. <https://doi.org/10.1097/mpg.0000000000000544>.
85. Patel R, DuPont H. New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. *Clin Infect Dis.* 2015;60 Suppl 2: S108-121. <https://doi.org/10.1093/cid/civ177>.
86. Абдурасулова И.Н., Софонова А.Ф., Сизов В.В., и др. Действие различных пробиотиков на двигательную и ориентировочно-исследовательскую активность крыс // Здоровье — основа человеческого потенциала: проблемы и пути их решения. — 2015. — Т. 10. — № 2. — С. 1047–1050. [Abdurasulova IN, Sofonova AF, Sizov VV, et al. Effect of probiotics on locomotor and orienting-exploratory activity of rats. *Zdorov'ye — osnova chelovecheskogo potentsiala: problemy i puti ikh resheniya.* 2015;10(2):1047-1050. (In Russ.)]
87. Абдурасулова И.Н., Тарасова Е.А., Мацулевич А.В., и др. Изменение качественного и количественного состава кишечной микробиоты у крыс в течение экспериментального аллергического энцефаломиелита // Российский физиологический журнал им. И.М. Сеченова. — 2015. — Т. 101. — № 11. — С. 1235–1249. [Abdurasulova IN, Tarasova EA, Matsulevich AV, et al. Changes in the qualitative and quantitative composition of gut microbiota in rats during experimental allergic encephalomyelitis. *Russian journal of physiology.* 2015;101(11):1235-1249. (In Russ.)]
88. Абдурасулова И.Н., Тарасова Е.А., Ермоленко Е.И., и др. *Enterococcus faecium* L3 корректирует микробиоту кишечника и модулирует иммунные функции у крыс с ЭАЭ и пациентов с рассеянным склерозом // Журнал неврологии и психиатрии им. С.С. Корсакова. — 2015. — Т. 115. — № 8–2. — С. 45–45. [Abdurasulova IN, Tarasova EA, Ermolenko EI, et al. *Enterococcus faecium* L3 korrektruet mikrobiotiku kishechnika i moduliruet immunnye funktsii u krys s EAE i patsientov s rassejannym sklerozom. *Zhurnal nevrologii i psikhiatrii im. SS Korsakova.* 2015;115(8-2):45-45. (In Russ.)]. <https://doi.org/10.17116/jnevro20151158245-102>.
89. Cowan C, Callaghan B, Richardson R. The effects of a probiotic formulation (*Lactobacillus rhamnosus* and *L. helveticus*) on developmental trajectories of emotional learning in stressed Infant rats. *Transl Psychiatry.* 2016;6(5): e823. <https://doi.org/10.1038/tp.2016.94>.
90. Foster J, Lyte M, Meyer E, Cryan J. Gut microbiota and brain function: an evolving field in neuroscience. *Int J Neuropsychopharmacol.* 2016;19(5). pii: pyv114. <https://doi.org/10.1093/ijnp/pyv114>.
91. Tomasik J, Yolken R, Bahn S, Dickerson F. Immunomodulatory effects of probiotic supplementation in schizophrenia patients: a randomized, placebo-controlled trial. *Biomark Insights.* 2015;10:47-54. <https://doi.org/10.4137/bmi.s22007>.
92. Severance E, Gressitt K, Stallings C, et al. Probiotic normalization of *Candida albicans* in schizophrenia: a randomized, placebo-controlled, longitudinal pilot study. *Brain Behav Immun.* 2017;62:41-45. <https://doi.org/10.1016/j.bbi.2016.11.019>.

93. Pirbaglou M, Katz J, de Souza R, et al. Probiotic supplementation can positively affect anxiety and depressive symptoms: a systematic review of randomized controlled trials. *Nutr Res.* 2016;36(9):889-898. <https://doi.org/10.1016/j.nutres.2016.06.009>.
94. McKean J, Naug H, Nikbakht E, et al. Probiotics and subclinical psychological symptoms in healthy participants: a systematic review and meta-analysis. *J Altern Complement Med.* 2017;23(4):249-258. <https://doi.org/10.1089/acm.2016.0023>.

---

✿ Authors and affiliations

**Irina G. Shalaginova** — Senior Lecturer, School of Life Science, Immanuel Kant Baltic Federal University, Kaliningrad, Russia. SPIN: 1160-1915. E-mail: shalaginova\_i@mail.ru.

**Liudmila V. Matskova** — PhD, Professor-Researcher, Microbiology and Biotechnology Unit of School of Life Science, Immanuel Kant Baltic Federal University, Kaliningrad, Russia. SPIN: 4756-7437. E-mail: liudmila.matskova@ki.se.

**Natalia M. Gunitseva** — Specialist in Bioengineering and Bioinformatics, School of Life Science, Immanuel Kant Baltic Federal University, Kaliningrad, Russia. E-mail: nat-gun@mail.ru.

**Irina A. Vakoliuk** — PhD, Associate Professor, School of Life Science, Immanuel Kant Baltic Federal University, Kaliningrad, Russia. SPIN: 2378-7129. E-mail: vakoluk@mail.ru.

---

✿ Информация об авторах

**Ирина Геннадьевна Шалагинова** — старший преподаватель, Институт живых систем, ФГАОУ ВО «Балтийский федеральный университет имени Иммануила Канта», Калининград. SPIN: 1160-1915. E-mail: shalaginova\_i@mail.ru.

**Людмила Валентиновна Мацкова** — профессор-исследователь, отдел микробиологии и биотехнологии института живых систем, ФГАОУ ВО «Балтийский федеральный университет имени Иммануила Канта», Калининград. SPIN: 4756-7437. E-mail: liudmila.matskova@ki.se.

**Наталья Михайловна Гуничева** — студентка специальности биоинженерия и биоинформатика. ФГАОУ ВО «Балтийский федеральный университет имени Иммануила Канта», Калининград. E-mail: nat-gun@mail.ru.

**Ирина Анатольевна Ваколюк** — канд. биол. наук, доцент, Институт живых систем, ФГАОУ ВО «Балтийский федеральный университет имени Иммануила Канта», Калининград. SPIN: 2378-7129. E-mail: vakoluk@mail.ru.